Published on 21/12/2025
How to Conduct Time-to-Event Analysis in Cohort Studies
Time-to-event analysis, also known as survival analysis, is essential for evaluating when an outcome of interest occurs in prospective cohort studies. For pharma professionals and clinical trial teams, understanding this statistical technique enables better insights into drug performance, safety timelines, and disease progression. This guide walks you through the principles, tools, and best practices in performing time-to-event analysis in real-world evidence (RWE) studies.
What is Time-to-Event Analysis?
Time-to-event analysis focuses not only on whether an event occurs but also on when it occurs. Events may include:
- Disease progression or remission
- Hospital admission or discharge
- Death or survival
- Treatment discontinuation or switching
- Adverse events
Each subject contributes time from study entry until the occurrence of the event or censoring (e.g., study end, loss to follow-up). The time dimension is central to this analysis, which distinguishes it from binary logistic regression or linear models.
Why Use Time-to-Event Methods in Prospective Cohorts?
Unlike retrospective designs, prospective cohort studies naturally track event timing. Time-to-event analysis leverages this advantage by allowing you to:
- Handle incomplete follow-up via censoring
- Compare survival probabilities between treatment arms
- Estimate hazard ratios (HRs) to quantify risk
- Model time-varying covariates
- Visualize trends using survival curves
This approach is especially critical in
Common Techniques in Time-to-Event Analysis
Several statistical tools are commonly used:
- Kaplan-Meier (KM) Curves: Estimate survival probabilities over time without adjusting for covariates.
- Log-Rank Test: Compares survival distributions between groups.
- Cox Proportional Hazards Model: Evaluates covariates’ effect on the hazard of the event, assuming proportionality.
- Nelson-Aalen Estimator: Useful for cumulative hazard function estimates.
Each method has its use case depending on the nature of the data and study goals.
Handling Censoring in Time-to-Event Data
Censoring occurs when an individual’s complete event history is not observed due to:
- Study ending before the event occurs
- Participant loss to follow-up
- Withdrawal from study
Right-censoring is most common and must be accounted for using appropriate methods like KM and Cox models. Ignoring censoring can severely bias the results.
Follow Pharma SOP guidelines for documenting censoring rules and assumptions in clinical research protocols.
Kaplan-Meier Curves: Step-by-Step
To generate a KM curve:
- Rank subjects by time to event
- Calculate survival probability at each event time
- Plot the step function for survival estimates
- Add confidence intervals and risk tables
KM plots offer intuitive visualizations of group differences and can be stratified by treatment, age, gender, or comorbidities.
Interpreting the Cox Proportional Hazards Model
The Cox model provides hazard ratios (HRs), interpreted as the relative risk of the event at any given time between two groups. For example:
- HR = 1: No difference
- HR > 1: Higher risk in the exposed group
- HR < 1: Lower risk in the exposed group
Always report the 95% confidence interval and p-value for the HR. Validate the proportional hazards assumption using Schoenfeld residuals or time-varying effects.
Ensure your modeling aligns with GMP documentation standards and prespecified statistical analysis plans.
Time-Dependent Covariates and Advanced Models
In real-world data, variables like medication dose, lab values, or compliance may change over time. Handle them using:
- Extended Cox models with time-dependent covariates
- Landmark analysis to reset time points
- Joint models linking longitudinal and survival data
These techniques increase accuracy but require careful planning and validation.
Visualizing and Reporting Time-to-Event Results
Follow reporting standards such as CONSORT or STROBE to include:
- KM plots with median survival times
- Tables of survival probability at fixed time points
- Hazard ratios with confidence intervals and p-values
- Number at risk over time
- Graphical checks of proportional hazards
Use color-coded curves, clear legends, and stratified plots to enhance interpretability. Label axes clearly and include event counts.
As per Health Canada guidance, all survival data must be derived from auditable and reproducible sources.
Real-World Example: Time to Disease Progression
Consider a study evaluating a cancer therapy’s effect on progression-free survival (PFS). Time-to-event analysis helps:
- Compare time to progression between treatment arms
- Adjust for baseline covariates like tumor stage
- Estimate median PFS for regulatory submission
Use Cox regression to compute hazard ratios for treatment effect and KM plots for visualization. Account for censoring due to patients lost to follow-up or alive without progression at study end.
Best Practices and Common Pitfalls
- Check assumptions: Proportional hazards must be validated
- Plan interim analysis: Use alpha spending to control Type I error
- Handle missing data: Use imputation or sensitivity analysis
- Document censoring rules: Ensure clarity and transparency
- Use sufficient sample size: Underpowered studies give wide confidence intervals
Always align statistical methods with pharma stability testing expectations for durability and reliability in outcome measurement.
Conclusion
Time-to-event analysis is indispensable for interpreting outcomes in prospective cohort studies. Whether using Kaplan-Meier plots, Cox regression, or advanced joint models, these techniques allow pharma professionals to assess not only whether a treatment works, but when it works. By handling censoring correctly, adhering to regulatory standards, and validating assumptions, your RWE study results will stand up to both clinical and regulatory scrutiny.